Gabor E Linthorst Selected Research

agalsidase beta

5/2015	Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
1/2013	Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage.
3/2012	Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
3/2012	Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
2/2011	Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
1/2011	Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
7/2007	Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gabor E Linthorst Research Topics

Disease

37	Fabry Disease (Fabry's Disease) 05/2017 - 01/2003
5	Renal Insufficiency (Renal Failure) 05/2015 - 08/2003
5	Disease Progression 03/2015 - 12/2010
3	Gaucher Disease (Gaucher's Disease) 03/2015 - 01/2003
3	Pain (Aches) 10/2013 - 07/2007
2	Chronic Kidney Failure (Chronic Renal Failure) 03/2015 - 01/2002
1	Spinal Cord Diseases 01/2019
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2019
1	Stroke (Strokes) 05/2015
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 05/2015
1	Heart Failure 03/2015
1	Hearing Loss (Hearing Impairment) 03/2015
1	Chronic Renal Insufficiency 02/2015
1	Cysts 02/2015
1	Small Fiber Neuropathy 10/2013
1	Neuralgia (Stump Neuralgia) 10/2013
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2013
1	Proteinuria 03/2012
1	Familial Azotemia 05/2010
1	Blood Platelet Disorders (Thrombocytopathy) 05/2010
1	Infections 01/2010
1	Muscular Diseases (Myopathy) 01/2010
1	Rhabdomyolysis 01/2010
1	Seizures (Absence Seizure) 01/2010
1	Wounds and Injuries (Trauma) 01/2010
1	Hyperthermia 01/2010
1	Substance-Related Disorders (Drug Abuse) 01/2010
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 02/2008
1	Uremia 01/2002

Drug/Important Bio-Agent (IBA)

9	alpha-Galactosidase (Beano)IBA 01/2012 - 01/2003
8	GalactosidasesIBA 05/2015 - 01/2011
7	agalsidase beta FDA Link 05/2015 - 07/2007
5	globotriaosylceramide (globotriosylceramide)IBA 05/2015 - 10/2004
5	AntibodiesIBA 03/2015 - 10/2004
4	Proteins (Proteins, Gene)FDA Link 02/2015 - 01/2003
4	globotriaosyl lysosphingolipidIBA 03/2013 - 01/2011
4	EnzymesIBA 01/2011 - 03/2005
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2011
2	CreatinineIBA 03/2012 - 01/2002
2	agalsidase alfaIBA 01/2011 - 07/2007
2	Indicators and Reagents (Reagents)IBA 12/2010 - 06/2007
1	SolventsIBA 03/2013
1	Advanced Glycation End ProductsIBA 10/2012
1	cyclo(Arg-Pro) (CI 4)IBA 03/2012
1	Immunoglobulin E (IgE)IBA 02/2011
1	Urea (Carbamide)FDA LinkGeneric 05/2010
1	Uremic ToxinsIBA 05/2010
1	ElectrolytesIBA 01/2010
1	DNA (Deoxyribonucleic Acid)IBA 01/2010
1	GlycolipidsIBA 07/2009
1	Pharmaceutical PreparationsIBA 06/2007
1	Neutralizing AntibodiesIBA 10/2004
1	Chloroquine (Aralen)FDA LinkGeneric 12/2003
1	Blood Group Antigens (Blood Groups)IBA 11/2003
1	Messenger RNA (mRNA)IBA 01/2003
1	LipidsIBA 01/2003
1	Thrombopoietin (c-mpl Ligand)IBA 01/2002

Therapy/Procedure

20	Enzyme Replacement Therapy 05/2017 - 07/2004
3	Therapeutics 10/2011 - 01/2003
2	Enzyme Therapy 10/2004 - 01/2003
1	Kidney Transplantation 03/2015
1	Secondary Prevention 03/2015
1	Immunomodulation 03/2015
1	Duration of Therapy 03/2013